By Fineline Cube 
Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine has received approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials. The vaccine is designed to prevent invasive infections caused by Hib, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, and other conditions.
Vaccine Overview
The Hib vaccine developed by Hualan is formulated by conjugating purified Hib capsular polysaccharide with tetanus toxoid protein. This formulation is presented in a freeze-dried form. The vaccine aims to induce an immune response against Hib, providing protection to vaccinated individuals.
Clinical Trial Approval
The approval from the NMPA marks a significant milestone in the development of Hualan’s Hib vaccine. The company is now poised to advance into clinical trials, which will evaluate the safety and efficacy of the vaccine in preventing Hib-related infections.-Fineline Info & Tech